Use of composite endpoints in thrombolysis trials of acute myocardial infarction.

[1]  Barr Jb,et al.  HOME OR AWAY? , 1964, Lancet.

[2]  T. Killip,et al.  Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. , 1967, The American journal of cardiology.

[3]  E. Veys,et al.  HL-A AND INFECTIVE SACROILEITIS , 1974 .

[4]  R. Freeman,et al.  NITROBLUE-TETRAZOLIUM TESTS , 1975, The Lancet.

[5]  J. Lowe,et al.  The Wavefront Phenomenon of Ischemic Cell Death: 1. Myocardial Infarct Size vs Duration of Coronary Occlusion in Dogs , 1977, Circulation.

[6]  T. Waterston.  FLUIDS FOR DIARRHŒA IN YOUNG CHILDREN , 1977, The Lancet.

[7]  P. Greenland,et al.  Selection and interpretation of diagnostic tests and procedures. Principles and applications. , 1981, Annals of internal medicine.

[8]  J. Fleiss,et al.  Risk stratification and survival after myocardial infarction. , 1983, The New England journal of medicine.

[9]  M. Pfeffer,et al.  Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. , 1985, Circulation.

[10]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.

[11]  W. Ganz,et al.  The thrombolysis in myocardial infarction (TIMI) trial. , 1985, The New England journal of medicine.

[12]  M. Simoons,et al.  IMPROVED SURVIVAL AFTER EARLY THROMBOLYSIS IN ACUTE MYOCARDIAL INFARCTION A Randomised Trial by the Interuniversity Cardiology Institute in The Netherlands , 1985, The Lancet.

[13]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico.,et al.  EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION , 1986, The Lancet.

[14]  P. Serruys,et al.  Preservation of global and regional left ventricular function after early thrombolysis in acute myocardial infarction. , 1986, Journal of the American College of Cardiology.

[15]  J. Ritchie,et al.  Risk stratification for 1 year survival based on characteristics identified in the early hours of acute myocardial infarction. The Western Washington Intracoronary Streptokinase Trial. , 1986, Circulation.

[16]  R M Whitlock,et al.  Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. , 1987, Circulation.

[17]  R Roberts,et al.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.

[18]  M. Pfeffer,et al.  Ventricular enlargement and reduced survival after myocardial infarction. , 1987, Circulation.

[19]  E. Braunwald.  The path to myocardial salvage by thrombolytic therapy. , 1987, Circulation.

[20]  Harold T. Dodge,et al.  Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase* , 1987 .

[21]  E. Topol,et al.  A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. , 1987, The New England journal of medicine.

[22]  E. Braunwald,et al.  Six- and twelve-month follow-up of the phase I Thrombolysis in Myocardial Infarction (TIMI) trial. , 1988, The American journal of cardiology.

[23]  K. Lee,et al.  Insights derived from the thrombolysis and angioplasty in myocardial infarction (TAMI) trials. , 1988, Journal of the American College of Cardiology.

[24]  A. M. Skene,et al.  TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION Anglo-Scandinavian Study of Early Thrombolysis (ASSET) , 1988, The Lancet.

[25]  A. Jaffe,et al.  Prompt detection of myocardial injury by assay of creatine kinase isoforms in initial plasma samples , 1988, Clinical cardiology.

[26]  R. Norris,et al.  THERAPEUTIC TRIALS IN CORONARY THROMBOSIS SHOULD MEASURE LEFT VENTRICULAR FUNCTION AS PRIMARY END-POINT OF TREATMENT , 1988, The Lancet.

[27]  U. Tebbe,et al.  Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. , 1989, Journal of the American College of Cardiology.

[28]  E. Braunwald,et al.  Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded? , 1989, Circulation.

[29]  R. Gibbons,et al.  Serial quantitative planar technetium-99m isonitrile imaging in acute myocardial infarction: efficacy for noninvasive assessment of thrombolytic therapy. , 1989, Journal of the American College of Cardiology.

[30]  H. White,et al.  Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. , 1989, The New England journal of medicine.

[31]  E. Braunwald.  Enhancing thrombolytic efficacy by means of "front-loaded" administration of tissue plasminogen activator. , 1989, Journal of the American College of Cardiology.

[32]  L. Hillis,et al.  Prognosis after acute myocardial infarction in patients with and without residual anterograde coronary blood flow. , 1989, The American journal of cardiology.

[33]  J. Tijssen,et al.  Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5 year follow-up of a trial conducted by the Interuniversity Cardiology Institute of The Netherlands. , 1989, Journal of the American College of Cardiology.

[34]  M. Pfeffer,et al.  Ventricular Remodeling After Myocardial Infarction: Experimental Observations and Clinical Implications , 1990, Circulation.

[35]  E J Topol,et al.  Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials. , 1990, Circulation.

[36]  R. Califf,et al.  Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. , 1990, Circulation.

[37]  J. Griffin,et al.  Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis. , 1990, Circulation.

[38]  E. Braunwald,et al.  Risk stratification before thrombolytic therapy in patients with acute myocardial infarction. The Thrombolysis in Myocardial Infarction (TIMI) Phase II Co-Investigators. , 1990, Journal of the American College of Cardiology.

[39]  J. Berning,et al.  Early estimation of risk by echocardiographic determination of wall motion index in an unselected population with acute myocardial infarction. , 1990, The American journal of cardiology.

[40]  L. Becker.  Technetium-99m isonitrile tomography in patients with acute myocardial infarction: measurement of myocardial salvage by thrombolysis. , 1990, Journal of the American College of Cardiology.

[41]  E. Braunwald,et al.  Optimizing thrombolytic therapy of acute myocardial infarction. , 1990, Circulation.

[42]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  MEDICAL SCIENCE GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction , 1990, The Lancet.

[43]  J. Herlitz,et al.  Eligibility for intravenous thrombolysis in suspected acute myocardial infarction. , 1990, Circulation.

[44]  Thomas E. Moritz,et al.  Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting. Department of Veterans Affairs Cooperative Study on Antiplatelet Therapy. , 1990, Journal of the American College of Cardiology.

[45]  L. Tavazzi,et al.  GISSI-2: mortality plus extensive left-ventricular damage as "end-point" , 1990, The Lancet.

[46]  J. Gore,et al.  Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial. , 1991, Circulation.

[47]  K. Mann,et al.  Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. , 1991, Annals of internal medicine.

[48]  R. Norris,et al.  Point of view: use of left ventricular function as prognostic factor. , 1991, Circulation.

[49]  E. Braunwald,et al.  Does left ventricular ejection fraction following thrombolytic therapy have the same prognostic impact described in the prethrombolytic era? Results of the TIMI II trail , 1991 .

[50]  M. Perryman,et al.  Noninvasive detection of reperfusion in acute myocardial infarction based on plasma activity of creatine kinase MB subforms. , 1991, Journal of the American College of Cardiology.

[51]  L. Johnson,et al.  Effect of infarct size measured from antimyosin single-photon emission computed tomographic scans on left ventricular remodeling. , 1991, Journal of the American College of Cardiology.

[52]  Burton E. Sobel,et al.  Prevention of Arterial Reocclusion After Thrombolysis With Recombinant Lipoprotein‐Associated Coagulation Inhibitor , 1991, Circulation.

[53]  H. Hellstrom.  Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. , 1991, Circulation.

[54]  F. Sheehan,et al.  Does arterial patency 90 minutes following thrombolytic therapy predict 42 day survival , 1991 .

[55]  A. DeMaria,et al.  A Prospective, Randomized Trial Comparing Combination Half‐Dose Tissue‐Type Plasminogen Activator and Streptokinase With Full-Dose Tissue‐Type Plasminogen Activator , 1991, Circulation.

[56]  A. Remppis,et al.  Diagnostic Efficiency of Troponin T Measurements in Acute Myocardial Infarction , 1991, Circulation.

[57]  E. Haber,et al.  Platelet‐Targeted Fibrinolysis Enhances Clot Lysis and Inhibits Platelet Aggregation , 1991, Circulation.

[58]  M. Appleyard,et al.  Echocardiographic algorithms for admission and predischarge prediction of mortality in acute myocardial infarction. , 1992, The American journal of cardiology.

[59]  J. Lynch,et al.  Conjunctive Enhancement of Enzymatic Thrombolysis and Prevention of Thrombotic Reocclusion With the Selective Factor Xa Inhibitor, Tick Anticoagulant Peptide: Comparison to Hirudin and Heparin in a Canine Model of Acute Coronary Artery Thrombosis , 1992, Circulation.

[60]  E. Braunwald,et al.  Predictors of Early Morbidity and Mortality After Thrombolytic Therapy of Acute Myocardial Infarction: Analyses of Patient Subgroups in the Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase II , 1992, Circulation.

[61]  H. Anderson,et al.  Combination of Inhibition of Thrombin and Blockade of Thromboxane A2 Synthetase and Receptors Enhances Thrombolysis and Delays Reocclusion in Canine Coronary Arteries , 1992, Circulation.

[62]  J. Anderson,et al.  Does thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. Second Multicenter Thrombolysis Trial of Eminase in Acute Myocardial Infarction. , 1992, Journal of the American College of Cardiology.

[63]  V. Fuster,et al.  The pathogenesis of coronary artery disease and the acute coronary syndromes (2). , 1992, The New England journal of medicine.

[64]  E. Braunwald,et al.  An approach to evaluating thrombolytic therapy in acute myocardial infarction. The 'unsatisfactory outcome' end point. , 1992, Circulation.

[65]  M. Cerqueira,et al.  Long-term survival in 618 patients from the Western Washington Streptokinase in Myocardial Infarction trials. , 1992, Journal of the American College of Cardiology.

[66]  L. Becker,et al.  TIMI Perfusion Grade 3 but Not Grade 2 Results in Improved Outcome After Thrombolysis for Myocardial Infarction Ventriculographic, Enzymatic, Electrocardiographic Evidence From the TEAM‐3 Study , 1993, Circulation.

[67]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.

[68]  U. Tebbe,et al.  Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies. , 1993, Journal of the American College of Cardiology.